A 2025 clinical trial found a standardized Vitex extract improved postmenopausal sexual symptom scores, though medical experts advise caution regarding commercial products.
Researchers at Sri Venkateswara Hospital recently conducted a randomized placebo-controlled trial evaluating a specific Vitex extract for postmenopausal symptoms. The study took place between March 18 and July 15 of 2025 and was published in the journal Cureus.
For decades, clinical guidelines for menopausal symptom management have sharply separated established therapies from over-the-counter botanical products. The medical consensus has long viewed botanical supplements marketed for sexual wellbeing with deep caution. Federal health authorities maintain that evidence for chasteberry in treating menopausal symptoms remains preliminary. Official guidance states plainly that there is not enough reliable evidence to determine whether chasteberry helps sexual dysfunction.
The recent trial evaluated the effects of a botanical intervention over 60 days. The findings include:
The trial evaluated a specific preparation rather than a generic botanical category. The tested product was a 300-mg capsule standardized to 4.5 mg of agnuside. The paper reports that the tested composition was planned to be patented. This distinction matters deeply for women evaluating their options.
Results from one standardized extract should not automatically be treated as evidence for other products. A consumer cannot assume that a random chasteberry capsule or tincture will replicate these specific clinical results. Multi-ingredient supplements targeting perimenopause and menopause vary wildly in their composition and quality.
Standardization is a critical concept in botanical medicine. This process guarantees that every dose contains a specific amount of the designated active compound. In this trial, the target compound was agnuside. Without standardization, the potency of a plant extract can vary drastically based on growing conditions.
Soil quality, harvest timing, and processing methods all change the final chemical makeup of a raw plant. When a consumer buys an unstandardized product, she has no reliable way to verify what she is ingesting. The dosage might be too low to have any biological effect, or it might be unpredictably high. The trial's use of a standardized 300-mg capsule isolates the variable being tested.
This rigorous approach is necessary for scientific measurement, but it highlights a major flaw in the retail supplement market. Many retail products mask their exact botanical ratios behind proprietary blends.
The trial authors characterized their results as consistent with earlier clinical and pharmacological research. They called for larger, multicenter trials with longer treatment and follow-up periods. They also proposed several biological mechanisms to explain the results.
The authors describe the supplement as a possible neuroendocrine modulator involving dopaminergic pathways. They suggest it might interact with the hypothalamic-pituitary-gonadal axis. They also mention potential effects on prolactin, gonadotropins, and various neurotransmitter systems. These are theoretical mechanisms discussed by the authors rather than definitive biological facts established by this trial alone.
Interpreting the trial data requires distinguishing between a questionnaire score and a clinical diagnosis. The reported improvement in sexual symptoms is an encouraging signal. It should be described precisely as a questionnaire-domain finding.
Higher domain scores on the Menopause-Specific Quality of Life Questionnaire indicate a poorer quality of life. The reported reduction represents improvement within the study's specific scoring system. The trial did not establish that the botanical extract directly improves desire, arousal, orgasm, or lubrication. It did not measure total sexual activity or broader relationship satisfaction.
The study relied on the Blatt-Kupperman Index and the Menopause Rating Scale alongside the MENQOL assessment. These are validated clinical tools used globally to track subjective symptom severity over time. However, self-reported indices capture how a patient feels rather than measuring objective biological markers. A drop in a questionnaire score reflects a welcome subjective improvement for the patient.
It does not map directly to a permanent physical change in tissue health or systemic hormone levels. The trial also did not demonstrate superiority over established treatments for genitourinary or sexual symptoms. The researchers did not design the study to compare the extract with vaginal estrogen or other prescription therapies. It was not measured against lubricants, moisturizers, pelvic-floor care, psychotherapy, or sex therapy.
The study measured symptoms and quality-of-life domains over 60 days without any extended post-treatment follow-up. It did not show whether any measured benefits persist after supplementation stops.
The researchers applied strict medical exclusions during the screening process. They excluded women who had recently used hormone preparations or plant-based hormone substitutes. They also excluded those taking thyroid hormones, clonidine, anticoagulants, or antithrombotic agents. Women taking other menopause-related supplements were barred from participating.
The trial excluded women with hormone-related cancers, thyroid dysfunction, and abnormal uterine bleeding. Individuals with significant cardiovascular or thromboembolic disease were not eligible. Major hepatic or renal impairment disqualified potential participants. The sample was drawn exclusively from one hospital in India.
Researchers excluded people with a body mass index above 30 kilograms per square meter. This specific weight exclusion limits the direct relevance of the data. A significant portion of the adult female population falls outside of this narrow demographic bracket. Women actively navigating nutrition and weight management alongside menopausal changes will not find clear answers in this restricted sample.
These exclusions mean that the findings cannot automatically be generalized to women with those conditions. They also cannot be applied broadly to women taking the excluded medication categories. The modest sample size and single-center design limit the immediate applicability to the wider population of midlife women. A larger trial spanning multiple clinical centers would be necessary to confirm these preliminary numbers.
The internal inconsistency in the paper's safety reporting requires careful reading. The abstract claims that no adverse effects were observed during the trial. The detailed safety table lists multiple mild adverse events in both study groups. A statement that no adverse effects occurred in a small trial does not prove that a product is universally safe.
The 60-day duration is simply too short to detect uncommon or delayed harms. Public health guidance advises caution regarding chasteberry. Guidelines warn that the botanical may not be safe for women with hormone-sensitive conditions. This specifically includes breast, uterine, or ovarian cancer.
Authorities also state that use during pregnancy or breastfeeding may be unsafe. Reported short-term side effects include nausea and stomach pain alongside diarrhea, headache, and itching. Current safety guidance notes that chasteberry fruit extract has been used safely in research studies for up to three months. This observation does not establish safety for longer-term use or validate every commercial formulation on the market.
Women taking prescription medicines must speak with a health care professional before using herbal products. Herbs and medicines can interact in harmful ways. The trial's exclusion of participants on anticoagulants and antithrombotic agents highlights this safety principle. Any approach to intimate confidence and sexual wellbeing requires full visibility into a patient's medication list.
The paper's short-term findings sit within a much broader landscape of menopause care. Sexual wellbeing is rarely driven by one single biological variable. The experience of intimacy is heavily influenced by a network of physical, emotional, and environmental factors. Vasomotor symptoms, for example, can cause severe sleep deprivation.
Chronic sleep deprivation predictably lowers energy and blunts sexual desire. Vaginal or urinary symptoms often create physical apprehension. Anticipating pain naturally reduces arousal and can create a cycle of physical tension. Mood changes and general midlife fatigue further complicate the picture.
Certain medications prescribed for mood or blood pressure can carry side effects that directly suppress sexual function. Relationship context and accumulated daily stress also play massive roles in a woman's desire for intimacy. Treating sexual symptoms effectively requires looking at this entire physiological and emotional picture. A single capsule cannot address severe sleep deficits or repair relationship friction.
Relying on one supplement to resolve a complex web of physical changes oversimplifies midlife health. Comprehensive care requires integrating specific interventions into a broader plan that accounts for the patient's entire medical reality.
A woman interested in this botanical intervention can reasonably view this trial as an encouraging but early signal. It is not a definitive recommendation or a replacement for individualized medical care. Any decision to try a new supplement should involve a direct conversation with a clinician or pharmacist. Patients should discuss the exact product, dose, ingredient standardization, and intended duration.
They must ask specifically about hormone-sensitive conditions, thyroid treatment, and other centrally acting medicines. Sexual symptoms are worth assessing directly rather than assuming they stem entirely from a simple lack of desire. Vasomotor symptoms, physical pain, sleep disruption and mood changes all shape the physical experience of intimacy.
If discomfort or pain is present, a woman should describe its location, timing, and triggers to her provider. She should document any lubrication changes, urinary symptoms, and whether the symptoms persist after sexual activity. This level of detail helps a clinician assess possible genitourinary causes or other physical factors.
If low desire or reduced pleasure is the main concern, she should track the specific nature of the issue. It helps to clarify whether the tension centers on desire, arousal, orgasm, pain, or confidence. The trial's sexual-symptom score cannot distinguish among these varied physical and emotional experiences. Women should seek prompt medical evaluation for postmenopausal bleeding, new pelvic pain, or unexplained vaginal symptoms.
Breast or pelvic masses require immediate professional assessment.
This early clinical signal suggests that future practice will increasingly need to evaluate specific standardized botanical formulations alongside established treatments for midlife sexual wellbeing.
Assessing new botanical research for midlife sexual symptoms requires separating narrow clinical signals from broad commercial marketing. Refemina addresses the skin and hair changes mixed with aggressive anti-aging marketing, translating credible evidence into clear adult guidance so you can make informed decisions about your changing physiology. Explore Resources
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources